Delayed regional metabolic actions of phencyclidine

Gao Xue-Min Gao, Shirakawa Osamu Shirakawa, Du Fu Du, Carol A. Tamminga

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Phencyclidine (PCP), a psychotomimetic drug of abuse, produces mental changes and manifestations in humans which are reminiscent of schizophrenia, though the mechanism of these actions remains unknown. We report here a biphasic time course of PCP action on regional cerebral glucose metabolism extending over 48 h. A single dose of PCP (8.6 mg/kg) produces an initial increase in glucose metabolism (at 3 h) and a later decrease in glucose metabolism (at 24 h) without a return to baseline until 48 h. A single lower dose of PCP (0.86 mg/kg), a dose which is considered selective for action at the NMDA-PCP receptor, produces no early metabolic change (at 3 h), but replicates the regional hypometabolism albeit less intense at 24 h. The delayed cerebral hypometabolism does not appear to be related to PCP-induced intracellular vacuolization, seen in the retrosplenial cortex. These metabolic changes may be associated with the psychotomimetic effects of PCP and thus may be relevant to psychosis in humans.

Original languageEnglish (US)
Pages (from-to)7-15
Number of pages9
JournalEuropean Journal of Pharmacology
Volume241
Issue number1
DOIs
StatePublished - Sep 7 1993

Fingerprint

Phencyclidine
Glucose
Phencyclidine Receptors
Street Drugs
N-Methyl-D-Aspartate Receptors
Psychotic Disorders
Schizophrenia

Keywords

  • Glucose metabolism
  • Histopathology
  • Limbic system
  • Phencyclidine
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Delayed regional metabolic actions of phencyclidine. / Xue-Min Gao, Gao; Osamu Shirakawa, Shirakawa; Fu Du, Du; Tamminga, Carol A.

In: European Journal of Pharmacology, Vol. 241, No. 1, 07.09.1993, p. 7-15.

Research output: Contribution to journalArticle

Xue-Min Gao, Gao ; Osamu Shirakawa, Shirakawa ; Fu Du, Du ; Tamminga, Carol A. / Delayed regional metabolic actions of phencyclidine. In: European Journal of Pharmacology. 1993 ; Vol. 241, No. 1. pp. 7-15.
@article{fdc0335f8fa44e7f922fc32eeb62568f,
title = "Delayed regional metabolic actions of phencyclidine",
abstract = "Phencyclidine (PCP), a psychotomimetic drug of abuse, produces mental changes and manifestations in humans which are reminiscent of schizophrenia, though the mechanism of these actions remains unknown. We report here a biphasic time course of PCP action on regional cerebral glucose metabolism extending over 48 h. A single dose of PCP (8.6 mg/kg) produces an initial increase in glucose metabolism (at 3 h) and a later decrease in glucose metabolism (at 24 h) without a return to baseline until 48 h. A single lower dose of PCP (0.86 mg/kg), a dose which is considered selective for action at the NMDA-PCP receptor, produces no early metabolic change (at 3 h), but replicates the regional hypometabolism albeit less intense at 24 h. The delayed cerebral hypometabolism does not appear to be related to PCP-induced intracellular vacuolization, seen in the retrosplenial cortex. These metabolic changes may be associated with the psychotomimetic effects of PCP and thus may be relevant to psychosis in humans.",
keywords = "Glucose metabolism, Histopathology, Limbic system, Phencyclidine, Psychosis, Schizophrenia",
author = "{Xue-Min Gao}, Gao and {Osamu Shirakawa}, Shirakawa and {Fu Du}, Du and Tamminga, {Carol A.}",
year = "1993",
month = "9",
day = "7",
doi = "10.1016/0014-2999(93)90926-9",
language = "English (US)",
volume = "241",
pages = "7--15",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Delayed regional metabolic actions of phencyclidine

AU - Xue-Min Gao, Gao

AU - Osamu Shirakawa, Shirakawa

AU - Fu Du, Du

AU - Tamminga, Carol A.

PY - 1993/9/7

Y1 - 1993/9/7

N2 - Phencyclidine (PCP), a psychotomimetic drug of abuse, produces mental changes and manifestations in humans which are reminiscent of schizophrenia, though the mechanism of these actions remains unknown. We report here a biphasic time course of PCP action on regional cerebral glucose metabolism extending over 48 h. A single dose of PCP (8.6 mg/kg) produces an initial increase in glucose metabolism (at 3 h) and a later decrease in glucose metabolism (at 24 h) without a return to baseline until 48 h. A single lower dose of PCP (0.86 mg/kg), a dose which is considered selective for action at the NMDA-PCP receptor, produces no early metabolic change (at 3 h), but replicates the regional hypometabolism albeit less intense at 24 h. The delayed cerebral hypometabolism does not appear to be related to PCP-induced intracellular vacuolization, seen in the retrosplenial cortex. These metabolic changes may be associated with the psychotomimetic effects of PCP and thus may be relevant to psychosis in humans.

AB - Phencyclidine (PCP), a psychotomimetic drug of abuse, produces mental changes and manifestations in humans which are reminiscent of schizophrenia, though the mechanism of these actions remains unknown. We report here a biphasic time course of PCP action on regional cerebral glucose metabolism extending over 48 h. A single dose of PCP (8.6 mg/kg) produces an initial increase in glucose metabolism (at 3 h) and a later decrease in glucose metabolism (at 24 h) without a return to baseline until 48 h. A single lower dose of PCP (0.86 mg/kg), a dose which is considered selective for action at the NMDA-PCP receptor, produces no early metabolic change (at 3 h), but replicates the regional hypometabolism albeit less intense at 24 h. The delayed cerebral hypometabolism does not appear to be related to PCP-induced intracellular vacuolization, seen in the retrosplenial cortex. These metabolic changes may be associated with the psychotomimetic effects of PCP and thus may be relevant to psychosis in humans.

KW - Glucose metabolism

KW - Histopathology

KW - Limbic system

KW - Phencyclidine

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0027220288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027220288&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(93)90926-9

DO - 10.1016/0014-2999(93)90926-9

M3 - Article

C2 - 8223927

AN - SCOPUS:0027220288

VL - 241

SP - 7

EP - 15

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -